BeOne Medicines has clinched US accelerated approval for its drug sonrotoclax in a rare but aggressive form of blood cancer, where AbbVie and Genentech’s Venclexta is used off-label.
BeOne Medicines has clinched an accelerated approval for its drug sonrotoclax in mantle cell lymphoma (MCL), marking the start of its bid to challenge AbbVie …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Next-Gen BCL2 Inhibitor Approved for Aggressive Lymphoma
BeOne wins FDA approval in lymphoma race
Roche's ctDNA-guided approach in post-surgical bladder cancer pays off with Tecentriq nod
New AML Regimen for Unfit Patients Gets FDA's Blessing
Advancing Frontline Care With a Quadruplet Regimen for Transplant-Ineligible Myeloma Patients
Regenxbio says Duchenne gene therapy succeeded in clinical trial, paving way for FDA submission
With new data, Regenxbio to seek FDA approval of Duchenne gene therapy
AstraZeneca scores with Imfinzi in another bladder cancer trial, rivaling Merck's Keytruda
Astellas treatment offers new hope to a devastated rare disease community
Five years after disaster, a rare disease community gets new chance at treatment
Sonrotoclax (Beqalzi) indicated for relapsed or refractory mantle cell lymphoma
Diamantas takes the reins, Regenxbio stakes claim in Duchenne gene therapy, and more biotech news from The Readout
The companies developing Ebvallo reached an agreement with the FDA to address its main reason for rejecting the drug.
With the help of DNA testing company Natera and its personalized molecular residual disease (MRD) blood test Signatera, Roche’s…
All-oral combination indicated for patients ineligible for intensive chemotherapy
Almost two thirds of patients with T-cell acute lymphoblastic leukaemia involved in a clinical trial of the treatment are now…
